Pharmaceuticals

Chloroquine and hydroxycloroquine got the Food and Drug Administration's go-ahead to be put in the nation's strategic storehouses. But the drugs haven't been approved to treat coronavirus patients.

Gilead Science's remdesivir, an antiviral medicine being tested for treatment of COVID-19, would get a seven-year monopoly if approved by the Food and Drug Administration.

A new report finds insurers are becoming more selective about which medications they'll cover. Patients and doctors have to work harder to get treatments approved.

In China, drug manufacturers are getting back to work. But supply chain disruptions could still lead to drug shortages down the road.

Two nearly identical drug implants have very different prices. The one for kids has a list price of $37,300. For adults, it's $4,400. A dad fought for his daughter to be able to get the cheaper drug.

With drug costs on the rise — and insurers refusing to cover some prescriptions — even patients with insurance can find themselves facing high out-of-pocket costs or going without.

Changes in the way the Food and Drug Administration reviews new medicines means that there are more cures and treatments on the market. But there's also less proof the drugs are safe and effective.

Nearly 1 in 4 Americans has trouble affording prescription drugs, according to a Kaiser Family Foundation poll. Over the past decade, high prices of several medicines have become flashpoints.

A leukemia drug seemed to help patients with Parkinson's disease. But critics say the results are equivocal and could raise false hopes.

Infectious disease specialists debate whether it's better to give the strongest antibiotics all at once for drug-resistant germs or save the most innovative medicines for use as a last resort.

Dengue afflicts nearly 400 million people worldwide every year, but a vaccine has remained elusive. New research offers a path forward.

The agreement removes the drugmaker from the list of defendants in an upcoming federal opioid trial and follows an August settlement in Oklahoma in which it agreed to pay $572 million.